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Abstract
Survivors of childhood cancer treated with cranial irradiation are at risk of cerebro-
vascular disease (CVD), but the risks beyond age 50 are unknown. In all, 13457 survi-
vors of childhood cancer included in the population-based British Childhood Cancer
Survivor Study cohort were linked to Hospital Episode Statistics data for England.
Risk of CVD related hospitalisation was quantified by standardised hospitalisation
ratios (SHRs), absolute excess risks and cumulative incidence. Overall, 315 (2.3%) sur-
vivors had been hospitalised at least once for CVD with a 4-fold risk compared to
that expected (95% confidence interval [CI]: 3.7-4.3). Survivors of a central nervous
system (CNS) tumour and leukaemia treated with cranial irradiation were at greatest
risk of CVD (SHR = 15.6, 95% CI: 14.0-17.4; SHR = 5.4; 95% CI: 4.5-6.5, respec-
tively). Beyond age 60, on average, 3.1% of CNS tumour survivors treated with cra-
nial irradiation were hospitalised annually for CVD (0.4% general population).
Cumulative incidence of CVD increased from 16.0% at age 50 to 26.0% at age 65
(general population: 1.4-4.2%). In conclusion, among CNS tumour survivors treated
Abbreviations: AER, absolute excess risk; BCCSS, British Childhood Cancer Survivor Study; CCSS, Childhood Cancer Survivor Study; CI, confidence interval; CNS, central nervous system; CVD,
cerebrovascular disease; HES, hospital episode statistics; ICD, International Classification of Diseases; MRA, magnetic resonance angiography; MRI, magnetic resonance imaging; NHS, National
Health Service; RER, relative excess risk; RR, relative risk; SHR, standardised hospitalisation ratio.
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with cranial irradiation, the risk of CVD continues to increase substantially beyond
age 50 up to at least age 65. Such survivors should be: counselled regarding this risk;
regularly monitored for hypertension, dyslipidaemia and diabetes; advised on life-
style risk behaviours. Future research should include the recall for counselling and
brain MRI to identify subgroups that could benefit from pharmacological or surgical
intervention and establishment of a case-control study to comprehensively determine
risk-factors for CVD.
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1 | BACKGROUND
Survival after childhood cancer has markedly improved over the last
few decades with overall 5-year survival in the United Kingdom
now exceeding 80%.1 Although the number of long-term survivors
continues to increase, many subgroups of survivors are at risk of
developing adverse health conditions many years after treat-
ment.2,3 Circulatory conditions, including cerebrovascular disease
(CVD), are the leading cause of death among ageing survivors.4
Studies specifically investigating CVD in survivors have reported
substantively increased risks among survivors previously treated
with cranial radiotherapy, but only up to age 50.5-12 Beyond age
50, the risk of developing CVD in the general population doubles
every 10 years,13 but it is uncertain how the risk among survivors
of childhood cancer, particularly those treated with cranial radio-
therapy, develops with increasing age. If the relative risk
(RR) remains elevated into ages at which the risk of developing
CVD in the general population starts to increase substantially, then
a considerable number of survivors could be affected. To our
knowledge, this is the first large-scale study to quantify the risks of
CVD up to age 65 according to whether survivors were treated
with cranial radiotherapy or not.
The principal aim of our study was to determine the long-term
risks of hospitalisations due to CVD among 5-year survivors of child-
hood cancer—particularly among those treated with cranial
radiotherapy—through electronic linkage of the British Childhood
Cancer Survivor Study (BCCSS) with the national hospital episode sta-
tistics (HES) database.
2 | METHODS
2.1 | British Childhood Cancer Survivor Study
The BCCSS is a population-based cohort of 17 980 individuals diag-
nosed with a childhood cancer between 1940 and 1991 inclusive,
before age 15 years, in Great Britain and who survived for at least
5 years from diagnosis.14 The cohort was identified through the
population-based National Registry of Childhood Tumours.
2.2 | Hospital episode statistics
HES are a centralised data warehouse maintained by National Health
Service (NHS) Digital containing records of inpatient, outpatient and
accident and emergency admissions to NHS hospitals within
England.15 Records in HES are classified into hospital episodes which
relate to a period of care for a patient under a single consultant. Vari-
ables recorded in HES include: an episode start and end date, a pri-
mary diagnosis code and 19 additional subsidiary diagnosis codes
which may relate to the primary diagnosis or to other coexisting con-
ditions.16 Diagnosis codes are classified using the International Classi-
fication of Diseases 10th revision (ICD-10). The BCCSS cohort was
electronically linked by a third party (Northgate Solutions) to the inpa-
tient HES database covering inpatients episodes from 1 April 1997 to
31 December 2012 using NHS number, date of birth, postcode and
sex. Survivors who had died before 1 April 1997 (N = 2378) or who
were Scottish or Welsh residents (N = 2101) were excluded.
2.3 | Definition of CVD
The primary and 19 subsidiary diagnosis code fields for each inpatient
HES record were used to identify CVD related hospitalisations
What's New?
Many sub-groups of childhood-cancer survivors have an
increased risk of developing adverse health conditions later
in life. In our study, the authors found that patients who
were treated with cranial irradiation in childhood face a sub-
stantially greater risk of cerebrovascular disease after age
50. By age 65, as many as 26% of these patients will have
been hospitalised for a cerebrovascular event. These survi-
vors should therefore be counselled regarding lifestyle
behaviours to reduce this risk. They should also be regularly
monitored for hypertension, dyslipidaemia and diabetes.
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(ICD-10:I60-68). If an individual had multiple CVDs, then only the first
occurrence was considered except for analyses relating to the mean
cumulative count. Survivors with any hospitalisation recorded as
“sequelae of CVD” (ICD-10:I69), but no prior CVD recorded in HES
were excluded (N = 44); as such survivors most likely have had a prior
CVD before the HES database was available for linkage.
2.4 | Radiotherapy ascertainment
Information on initial radiotherapy treatment in the form of yes/no has
previously been abstracted from medical records for 74% of all survi-
vors in the cohort available for analyses. We assumed that any survivor
with a tumour site “brain” or “meninges” and who had been treated
with radiotherapy had been exposed to cranial irradiation. Any leukae-
mia survivor treated with radiotherapy before 1991 was assumed to
have received prophylactic cranial irradiation unless information in the
medical record unequivocally stated that no radiotherapy was given.
Survivors who had received radiotherapy for a tumour other than a
central nervous system (CNS) tumour or leukaemia that was within the
neck or head region were considered as having received “head and
neck” radiotherapy. For survivors of any other tumour site—regardless
of whether they were treated with radiotherapy or not—we assumed
that they had not been exposed to cranial irradiation or radiation to the
head and neck. Separate analyses were conducted for CNS tumour, leu-
kaemia and head and neck tumour survivors treated with radiotherapy
as these were assumed a priori to be at high risk. Analyses for Hodgkin
lymphoma survivors treated with radiotherapy were not conducted as
it was not possible to accurately determine the site of the radiation.
2.5 | Statistical methods
Survivors entered the period at risk at 1 April 1997 and exited at the
earliest occurrence of: death, loss-to follow-up, hospitalisation for
CVD, or 31 December 2012 (study end date). CVD-related
hospitalisation rates for the general population were derived from the
entire (anonymised) HES dataset by dividing the number of individuals
with a hospitalisation by the mid-year general population estimates
for each age (1-year bands), sex and calendar-year (1-year bands).17
The accumulated person-years within each age, sex and calendar year
stratum in the survivor cohort were multiplied by the corresponding
general population rates to obtain the expected number of CVD
hospitalisations. The risks of hospitalisation due to CVD were quanti-
fied by standardised hospitalisation ratios (SHRs) and absolute excess
risks (AERs). The SHR was defined as the number of observed divided
by the number of expected CVD hospitalisations. The AER was
defined as the number of observed CVD hospitalisations minus the
number of expected CVD hospitalisations divided by the number of
person-years at risk and then multiplied by 10 000. The AER may be
interpreted as the number of additional hospitalisations per year per
10 000 survivors attributable to the original childhood cancer diagno-
sis or its treatment. SHRs and AERs were stratified by the following
factors: sex, type of childhood cancer,18 age at childhood cancer
diagnosis (0-3/4-7/9-11/12-14 years), period of cancer diagnosis
(<1970/1970-74/1975-79/1980-84/1985-91), attained age (<20/20-
29/30-39/40-49/50-59/≥60 years) and cranial radiotherapy (yes/no).
To investigate the simultaneous effect of potential risk factors of
CVD, a multivariable Poisson regression model with the log of the
expected number of CVD hospitalisations as the offset was used to
estimate the RRs.19 RRs can be interpreted as the ratio of the SHRs
adjusted for potential confounders. A similar multivariable Poisson
regression model but with the offset being the ln(person-years) and
the link function: ln(μ j−d

jÞ , where μj is the observed and dj the
expected number of CVDs for stratum j of a relevant factor, was fitted
to estimate relative excess risks (RERs).20 RERs can be interpreted as
the ratio of the AERs adjusted for potential confounders. Negative
binomial regression was used instead of Poisson regression when the
model fit showed signs of overdispersion. A likelihood-ratio test was
used to test for linear trend of a factor by comparing the deviance of
a model including the factor variable of interest, which was coded
using consecutive nonnegative integer values (eg, 0/1/2/3), to the
deviance of a model without the factor variable of interest. The
cumulative incidence of the first occurrence of being hospitalised for
CVD was calculated taking into account the competing risk of
death.21 In addition, the mean cumulative count (MCC) of being hos-
pitalised for a CVD including for any recurrent CVDs was calcu-
lated.22 The MCC can be interpreted as the average number of CVD
hospitalisations per survivor. Statistical significance was taken at the
5% level (two-sided test). All statistical analyses were conducted in
Stata statistical software version 16 except for the MCC which was
conducted in R.
N = 17 980
5-year survivors;
age 0-14 years
at diagnosis
N = 15 602
N = 13 501
N = 13 457
Died or were lost to
follow-up before the study
start date: 01 April 1997
Survivors who were
alive and Welsh
or Scottish residents
Had sequelae of
cerebrovascular disease
recorded, but no
previous cerebrovascular
event in HES
N = 2378
N = 2101
N = 44
F IGURE 1 Flow diagram showing exclusions for the cohort of
British Childhood Cancer Survivor Study linked with HES
REULEN ET AL. 3
3 | RESULTS
3.1 | Cohort characteristics
Of the 17 980 childhood cancer survivors in the cohort, 13 457 (74.8%)
were eligible for linkage with HES (Figure 1). The total follow-up
was 200 146 person-years with a median follow-up time of
15.8 years. Overall, 315 (2.3%) survivors had been hospitalised at
least once for CVD with 20% (N = 63) of all survivors hospitalised at
least twice. CVD was most common after a CNS tumour (N = 186;
59%), leukaemia (N = 57; 18%) and Hodgkin lymphoma (N = 17; 5%)
(Table 1).
TABLE 1 Observed and expected numbers of any cerebrovascular hospitalisations, standardised hospitalisation ratios and absolute excess
risks for all childhood cancer survivors combined
Any cerebrovascular hospitalisation
No O/E SHR (95% CI) AERa (95% CI)
Overall 13 457 315/78.9 4.0 (3.7,4.3) 11.8 (10.6,13.1)
Sex Male 7347 183/47.7 3.8 (3.3,4.4) 12.4 (10.2,15.1)
Female 6110 132/31.1 4.2 (3.6,5.0) 11.0 (8.8,13.8)
Pheterogeneity .382 .426
Type of childhood cancerb CNS tumour 2885 186/19.6 9.5 (8.2,10.9) 40.7 (34.7,47.8)
Leukaemia 3544 57/12.2 4.7 (3.6,6.0) 8.4 (6.0,11.7)
Hodgkin's lymphoma 961 17/7.0 2.4 (1.5,3.9) 7.0 (3.1,15.7)
Soft tissue sarcoma 691 12/6.7 1.9 (1.0,3.7) 4.1 (1.0,16.3)
Non-Hodgkin lymphoma 922 9/4.7 1.8 (1.0,3.2) 3.9 (1.1,13.7)
Wilms tumour 605 9/5.9 1.6 (0.7,3.8) 2.0 (0.2,21.3)
Others 1198 8/8.4 1.5 (0.8,2.9) 1.7 (0.3,11.4)
bone sarcoma 508 6/4.2 1.4 (0.6,3.2) 2.4 (0.2,33.1)
neuroblastoma 1169 5/3.1 1.0 (0.5,1.9) 0.0
NH-retinoblastoma 549 4/4.2 1.0 (0.4,2.6) 0.0
H-retinoblastoma 425 2/3.0 0.7 (0.2,2.7) 0.0
Pheterogeneity <.001 <.001
Age at diagnosis (y) 0-3 5322 78/25.0 3.1 (2.5,3.9) 6.6 (4.8,9.2)
4-8 3301 92/16.2 5.7 (4.6,7.0) 15.4 (12.0,19.8)
9-11 2549 83/16.9 4.9 (4.0,6.1) 17.7 (13.5,23.2)
12-14 2285 62/20.7 3.0 (2.3,3.8) 12.2 (8.4,17.8)
Ptrend .827 .001
Decade of diagnosis <1970 2484 102/38.8 2.6 (2.2,3.2) 17.7 (12.9,24.2)
1970-1974 1640 47/9.9 4.8 (3.6,6.3) 15.4 (10.7,22.1)
1975-1979 2148 53/9.0 5.9 (4.5,7.7) 13.6 (9.9,18.9)
1980-1984 2599 69/7.7 8.9 (7.1,11.3) 15.7 (12.0,20.5)
1985-1991 4586 44/13.5 3.3 (2.4,4.4) 4.4 (2.9,6.8)
Ptrend <.001 <.001
Attained age (y) <20 164 18/8.7 2.1 (1.3,3.3) 3.2 (1.3,7.9)
20-29 2584 57/7.0 8.2 (6.3,10.6) 8.0 (5.9,10.7)
30-39 4615 89/14.3 6.2 (5.0,7.6) 12.4 (9.7,15.9)
40-49 3804 72/20.1 3.6 (2.8,4.5) 16.0 (11.6,22.0)
50-59 1601 56/19.0 3.0 (2.3,3.8) 28.8 (19.4,42.8)
60+ 689 23/9.9 2.3 (1.6,3.5) 45.0 (22.0,92.0)
Ptrend .014 <.001
Abbreviations: AER, absolute excess risk; CI, confidence interval; O/E, observed/expected; SHR, standardised hospitalisation ratio.
aAERs per 10 000 person-years.
bChildhood cancer types as defined by the International Childhood Cancer Classification, version 3.
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3.2 | All survivors
All survivors combined had a 4-fold risk of being hospitalised for CVD
compared with expected (95% confidence interval [CI]: 3.7-4.3)
(Table 1). Of all types of childhood cancer, survivors of CNS tumours
were at the greatest risk of CVD (SHR = 9.5, 95% CI: 8.2-11.0,
AER = 40.7); whilst those treated for leukaemia (SHR = 4.7, 95% CI:
3.6-6.1, AER = 8.4), Hodgkin lymphoma (SHR = 2.4, 95% CI:1.5-3.9,
AER = 7.0) and soft tissue sarcoma (SHR = 1.8, 95% CI: 1.0-3.2,
AER = 3.9) had significant excess risks but of reduced magnitude. The
SHR of developing CVD declined significantly with increasing attained
age (Ptrend = .014), but was still 2.3-fold at ages 60 and older (95% CI:
1.6, 3.5). In contrast, the AER increased significantly with increasing
attained age (Ptrend < .001) from 3 (per 10 000 person-years) among
those aged <20 years to 45 among those aged ≥60 years. These
trends with attained age were confirmed in multivariable analyses
(Table S1).
3.3 | CNS tumour survivors
CNS tumour survivors treated with cranial irradiation had 15-fold the
expected risk of any CVD (95% CI: 14.0-17.4); corresponding to
73 excess hospitalisations per 10 000 person-years (95% CI:
65.0-82.4) (Table 2). The SHR was still more than 8-fold that expected
after age 60 (95% CI: 4.7-15.4). The AER increased significantly with
attained age reaching 130 for all CNS tumour survivors combined
after age 60 and more than 270 for those treated with cranial irradia-
tion. Every year, on average 3.1% (rateobserved = 3.07 per 100 person-
years) of CNS tumour survivors who received cranial irradiation and
survived beyond 60 years of age were hospitalised for CVD, whereas
only 0.4% (rateexpected = 0.36 per 100 person-years) was expected.
CNS tumour survivors treated without cranial radiotherapy were at
3-fold risk compared with expected (95% CI: 2.2-3.9), but the AER
never exceeded 30 at any age. SHRs and AERs did not vary signifi-
cantly by CNS tumour subtype (all P ≥ .43). Any significant trends in
SHRs and AERs observed by age at diagnosis and decade of treatment
were not confirmed in multivariable analyses (Table S2). Among CNS
tumour survivors treated with cranial irradiation the cumulative inci-
dence of CVD was 11.6% (95% CI: 8.6-15.0) by age 40, increased to
16.0% (95% CI: 12.7-19.6) by age 50 and reached 26.0% (95% CI:
21.4-30.8) by age 65, whilst only 4.2% was expected by age 65 (Fig-
ure 2). At that age the MCC was 0.35 (95% CI: 0.28, 0.43) meaning
that by age 65 the average number of CVD hospitalisations per CNS
tumour survivor treated with cranial irradiation was 0.35 (Figure 3).
For CNS tumour survivors not treated with cranial irradiation the
cumulative incidence reached 6.5% (95% CI: 3.5-10.8) by age 65.
When evaluating the cumulative incidence by CNS tumour subtype,
29.1% (95% CI: 21.5-37.2) of astrocytoma survivors treated with cra-
nial irradiation had developed CVD by age 65; few medulloblastoma
survivors had survived up to age 65, but the cumulative incidence was
already 24.5% (95% CI: 17.2-32.5) by age 60 (vs 2.9% expected)
(Figure 4).T
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3.4 | Leukaemia survivors
Among leukaemia survivors treated with cranial radiotherapy the SHR
was five times that expected (95% CI: 4.5-6.5) (Table 3). In absolute
terms, this equated to 10 excess hospitalisations per 10 000 person-
years with the AER increasing up to 18 by age 40 years (Ptrend = .002)
(Table 3; Table S3). The cumulative incidence for leukaemia survivors
previously treated with cranial irradiation was 3.9% (95% CI: 2.6-5.4)
by age 50 years and substantially above that expected (1.4%)
(Figure 2).
3.5 | Head and neck tumour survivors
The 736 survivors who were previously diagnosed with a tumour in
the head and neck region and treated with radiotherapy (Table S4)
were at 2-fold the expected risk (95% CI: 1.2-4.1; 10 CVD events).
The cumulative incidence reached 4.7% (95% CI: 1.6-10.4) for this
group by age 65 (Figure 2).
4 | DISCUSSION
4.1 | Main findings
Evidence is provided—to our knowledge for the first time—that both
the absolute risk and the excess number of inpatient hospitalisations
for CVD, among survivors of a childhood CNS tumour treated with
cranial irradiation, increases substantially beyond age 50 up to at least
age 65. By age 65, more than a quarter of such survivors have been
hospitalised. Each year lived by such survivors aged over 60 years
results in 3% being hospitalised, whilst only 0.4% would be expected.
26.0% (95%CI:21.4,30.8)
6.5% (95%CI:3.5,10.8)
3.9% (95%CI:2.6,5.4)
4.7% (95%CI:1.6,10.4)
  
4.2% (95%CI:2.9,5.9)
expected: 4.2%
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Importantly, we know that the absolute risk of 26% affected by age
65 is an underestimate of the true risk because an independent study
of the completeness of ascertainment of cardiovascular disease using
HES reported that 71% (95% CI: 62%-79%) of clinically ascertained
and confirmed CVD were independently ascertained by HES.23 In
particular, fatal CVD which occur outside of a hospital setting are
unlikely to be captured. To investigate the impact of this particular
type of under-ascertainment, we identified such deaths because the
cohort is also linked to the national death registry.24 Including such
events resulted in the cumulative incidence of CVD by age
24.5%
(95%CI:17.2,32.5)
29.1%
(95%CI:21.5,37.2)
19.2%
(95%CI:6.3,37.4)
4.4%
 
 2.9%
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TABLE 3 Observed and expected numbers of any cerebrovascular related hospitalisation overall among leukaemia survivors, standardised
hospitalisation ratios and absolute excess risks
Any Cerebrovascular hospitalisation Treated with cranial radiotherapy
No O/E SHR (95% CI) AERa (95% CI) O/E SHR (95% CI) AERa (95% CI)
Overall 3544 57/12.2 4.7 (3.9,5.6) 8.4 (6.6,10.6) 55/10.2 5.4 (4.47,6.5) 9.5 (7.55,11.95)
Sex Male 1856 33/6.9 4.8 (3.4,6.7) 9.4 (6.1,14.5) 32/5.8 5.6 (3.9,7.9) 10.7 (7.0,16.3)
Female 1688 24/5.3 4.5 (3.0,6.8) 7.3 (4.4,12.2) 23/4.4 5.2 (3.4,7.8) 8.2 (5.0,13.7)
Pheterogeneity .866 .454 .793 .437
Age at diagnosis (years) 0-3 1575 28/5.0 5.6 (3.9,8.2) 9.7 (6.2,15.1) 27/4.2 6.5 (4.5,9.5) 10.9 (7.0,17.1)
4-8 1157 17/3.8 4.5 (2.8,7.2) 7.6 (4.1,13.9) 16/3.3 4.9 (3.0,8.0) 8.1 (4.4,15.0)
9-11 533 10/2.1 4.8 (2.6,8.9) 10.0 (4.6,21.9) 10/1.7 6.0 (3.2,11.1) 12.1 (5.7,25.4)
12-14 279 2/1.4 1.5 (0.4,5.8) 1.5 (0.0,126.8) 2/1.1 1.8 (0.4,7.1) 2.4 (0.1,58)
Ptrend .071 .308 .103 .376
Decade of diagnosis <1970 70 0/0.8 — — 0/0.2 — —
1970-1979 1033 24/4.5 5.4 (3.6,8.0) 12.4 (7.6,20.3) 23/4.0 5.75 (3.8,8.7) 13.2 (8.0,21.6)
1980-1991 2441 33/6.9 4.8 (3.4,6.7) 7.1 (4.6,10.9) 32/6.0 5.34 (3.8,7.5) 8.0 (5.2,12.3)
Ptrend .321 .351 .834 .232
Attained age (years) <20 75 7/3.3 2.1 (1.0,4.5) 3.4 (0.9,13.7) 6/2.6 2.3 (1.0,5.1) 3.9 (0.9,15.9)
20-29 971 18/2.5 7.3 (4.6,11.6) 6.9 (4.1,11.9) 18/2.3 8.0 (5.0,12.7) 7.7 (4.6,13.1)
30-39 1571 23/3.7 6.3 (4.2,9.5) 12.3 (7.6,20.0) 23/3.4 6.8 (4.5,10.2) 13.5 (8.4,21.8)
40+ 927 9/2.8 3.2 (1.7,6.1) 14.0 (5.4,36.4) 8/2.0 4.0 (2.0,8.1) 18.0 (7.2,45.1)
Ptrend .215 .016 .14 .012
Abbreviations: AER, absolute excess risk; CI, confidence interval; O/E, observed/expected; SHR, standardised hospitalisation ratio.
aAERs per 10 000 person-years.
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65 increasing by 1% to 27%. There was no evidence that the excess
risk varied with age or decade at which cranial irradiation was
received.
4.2 | Previous studies
Recently, the North-American Childhood Cancer Survivor Study
(CCSS)6 reported risks of self-reported CVD up to age 50 with a
cumulative incidence of 19.9% for survivors at high risk. A French
study demonstrated that 11.3% of survivors treated with high-dose
cranial irradiation with doses exceeding 10 Gray to the major intracra-
nial vessels developed CVD by age 45.8 A Dutch study including
28 strokes found a cumulative incidence of 10.0% for developing
stroke by age 45 among survivors treated with cranial irradiation
only.12 The cumulative incidence figures from these studies are con-
sistent with the 13.4% and 16.0% cumulative incidence at age 45 and
50, respectively, for survivors of a CNS tumour treated with cranial
irradiation we report here. However, the current study shows that the
cumulative incidence of CVD continues to increase substantially
beyond age 50 years up to 26.0% by age 65.
The 4-fold overall increased SHR of CVD among all survivors in
our study was similar to that observed in the Scandinavian ALiCCS
study25; the only other large-scale population-based study investigat-
ing long-term risks of CVD hospitalisations. Consistent with our study,
the ALiCCS study also demonstrated that the AER of developing CVD
increases substantially with attained age, although our study did not
report risk estimates by whether survivors had been treated with cra-
nial irradiation.
In our study, CNS tumour survivors treated without cranial irradia-
tion were still at excess risk of CVD, although the risks were much
lower than among those treated with cranial irradiation. This is
consistent with data reported from the CCSS,5 although the risk when
compared with siblings was 13-fold (95% CI: 4.8-34.5) within the
CCSS; much higher than the 3-fold increased SHR we report here.
Notably, the risks among survivors treated without cranial irradiation
were mainly high in the first few decades after 5-year survival, but did
not appear to increase substantially with increasing attained age.
Several studies among survivors of childhood cancer demon-
strated strong dose-response relationships between the cumulative
radiation dose to the brain and risk of CVD.5,8-12 Intracranial vascular
damage—including stenosis constricting blood flow and aneurysms—is
common after high-dose cranial radiation involving the major cranial
blood vessels,26 although the exact mechanism by which cranial irradi-
ation may increase the risk of CVD is unclear.
Children's Oncology Group survivorship guidelines27 from the
USA indicate that survivors treated with cranial radiotherapy with
doses exceeding 18 Gray should be considered for brain magnetic res-
onance imaging (MRI) with magnetic resonance angiography (MRA) as
clinically indicated. Current childhood cancer survivorship guidelines
from the United Kingdom do not make reference to surveillance for
CVD.28 In the general population, silent CVD is 10 times more preva-
lent than symptomatic stroke29 and it is conceivable that the
prevalence of silent CVD would be even greater in the survivor popu-
lation. In a study30 among 132 paediatric patients treated with brain
radiotherapy 41.6% showed microbleeds or cavernomas after a mean
follow-up of only 11 years—which is a remarkably large percentage
considering the young age of these patients. In studies among individ-
uals from the general population the risk of developing a symptomatic,
mainly ischaemic, stroke after a silent brain infarct was 1.5- to
3.3-fold.31
4.3 | Implications for clinical practice
As reported in a recent review,32 there is suggestive evidence that
conditions which predispose to CVD such as hypertension,
dyslipidaemia and diabetes are more common33,34 and tend to
develop at younger ages among childhood cancer survivors as com-
pared with siblings or the general population.35-37 Therefore, to avoid
the potential for underdiagnosis, it would be prudent that survivors
who received cranial irradiation are regularly monitored for such con-
ditions. The review32 also identified suggestive evidence of lifestyle
factors being important in terms of reducing the risk of cardiovascular
conditions among survivors, in particular exercise38 and diet.33
Smoking and alcohol consumption are risk factors for stroke in the
general population.39,40 Therefore, regular counselling in follow-up
clinics in relation to exercise, diet, smoking and alcohol would be pru-
dent from a precautionary perspective. However, most previous work
relates to cardiac disease and there is a need for detailed aetiological
studies concerning CVD.
4.4 | Implications for further research
A question raised by such a large absolute risk (26% affected by age
65) is whether some form of screening (eg, MRA) to detect abnormali-
ties whilst asymptomatic would be beneficial to survivors. However,
this immediately begs the question—if abnormalities are found, is
there a suitable intervention to prevent or reduce the risk of symp-
tomatic CVD developing? At present, we do not know the answer to
this question and in particular we do not have an understanding of
the developmental processes leading to CVD. A first step should prob-
ably involve investigating intracranial vasculature abnormalities pre-
sent in those at greatest excess risk—survivors of CNS tumours which
were cranially irradiated and aged over 50, or possibly younger. The
recall of this national high-risk group for counselling and a brain MRI
(with MRA) to characterise the nature and extent of intracranial vas-
culature abnormalities needs serious consideration. The motivation
for such an undertaking is to determine whether a subgroup can be
identified for whom pharmacological or surgical intervention could
bring preventive/risk reduction benefit. For example, there is recent
evidence that suggests that surgical revascularisation in moya-moya
substantially reduces the risk of further stroke.41-45 To fully under-
stand the aetiology of CVD after cancer when young, we propose to
undertake a large population-based nationwide case-control study to
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determine the role of cumulative dose of radiation to the intracranial
vasculature, cumulative dose of individual cytotoxics, surgery for can-
cer, genotypic factors, age, gender, ethnicity, co-morbidities and poten-
tially modifiable risk factors including smoking, alcohol, waist-to-hip
ratio, diet and physical activity. We have previously published on the
substantial risk of CVD among survivors of teenage and young adult
cancer which revealed that by age 60 9%, 6% and 5% of CNS tumour,
head and neck cancer and leukaemia survivors, respectively, had been
hospitalised with CVD whereas 2% were expected.46 The case-control
study would be nested within the entire national population-based
childhood, teenage and young adult cohort combined.
4.5 | Study limitations
A limitation of this cohort study concerns the limited information
available relating to cumulative exposure of the intracranial vascula-
ture to radiation as a result of radiotherapy, but we plan to address
this in the planned case-control study. Additionally, as a result of the
level of ascertainment of events specified as haemorrhagic or infarc-
tion differing between observed and expected, we could not investi-
gate excess risks for these different types of events because of the
potential for bias in the SHR and AERs. It should also be acknowl-
edged that the risks presented here relate to survivors treated three
or more decades ago and that the risks might not be translatable to
survivors treated more recently. Current radiation regimes, tech-
niques, modalities and volumes have changed with more conformal
techniques minimising non-target tissue radiation exposure, hence the
risks presented here may be an overestimate of the risk of CVD for
patients treated more recently with cranial radiotherapy.
4.6 | Conclusions
Among CNS tumour survivors treated with cranial irradiation, the risk
of developing CVD increases substantially between age 40 and
65 years. Clinically, such survivors should be: counselled with regards
to the substantially increased risk; regularly monitored for hyperten-
sion, dyslipidaemia and diabetes; and advised on the potential benefits
of exercise, healthy diet, smoking cessation and drinking within guide-
lines. Future research among such survivors should include: the recall
for counselling and brain MRI (including MRA) of those aged
50 years—or possibly younger—to identify subgroups that could
potentially benefit from pharmacological or surgical intervention; and
establishment of a large-scale case-control study to determine the
aetiology of CVD for future prevention or intervention.
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